Ocrevus's Role in MS Battle May Signal Promising Trend.
With a list price that is 25% less than a competing drug, better outcomes, and less frequent dosing, maybe Ocrevus will start a new trend: better outcomes, easier administration-and a lower price. That trifecta is great news for people managing the cost and quality of MS care.